Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

Key Inclusion Criteria:

• Liver biopsy consistent with NASH and bridging (F3 fibrosis) according to the NASHClinical Research Network (CRN) classification in the opinion of the central reader

• Has the following laboratory parameters at the screening visit:

• Alanine aminotransferase (ALT) ≤ 8 x upper limit of normal (ULN)

• Creatinine Clearance (CLcr) ≥ 30 milliliter/minute (mL/min), as calculated by theCockcroft-Gault equation

• Hemoglobin A1c (HbA1c) ≤ 9.5% (or serum fructosamine ≤ 381 μmol if HbA1c isunable to be resulted)

• Total bilirubin ≤ 1.3 x ULN (unless an alternate etiology such as Gilbert'ssyndrome or hemolytic anemia is present)

Key Exclusion Criteria:

• Prior history of decompensated liver disease including clinical ascites, hepaticencephalopathy (HE), or variceal bleeding

• Child-Pugh (CP) score > 6, as determined at screening, unless due to therapeuticanti-coagulation

• Model for End-stage Liver Disease (MELD) score > 12, as determined at screening,unless due to therapeutic anti-coagulation

• Other causes of liver disease including, but not limited to, alcoholic liver disease,hepatitis B, hepatitis C, autoimmune disorders, drug-induced hepatotoxicity, Wilsondisease, iron overload, and alpha-1-antitryspin deficiency, based on medical historyand/ or centralized review of liver histology.

• History of liver transplantation

• Current or history of hepatocellular carcinoma (HCC) Note: Other protocol defined Inclusion/Exclusion criteria may apply.